Titre : Endostatines

Endostatines : Questions médicales fréquentes

Termes MeSH sélectionnés :

C-Reactive Protein
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Endostatines : Questions médicales les plus fréquentes", "headline": "Endostatines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Endostatines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-17", "dateModified": "2025-03-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Endostatines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines angiostatiques", "url": "https://questionsmedicales.fr/mesh/D043165", "about": { "@type": "MedicalCondition", "name": "Protéines angiostatiques", "code": { "@type": "MedicalCode", "code": "D043165", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.100.450" } } }, "about": { "@type": "MedicalCondition", "name": "Endostatines", "alternateName": "Endostatins", "code": { "@type": "MedicalCode", "code": "D043169", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Tapan Behl", "url": "https://questionsmedicales.fr/author/Tapan%20Behl", "affiliation": { "@type": "Organization", "name": "Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India." } }, { "@type": "Person", "name": "Lifang Guo", "url": "https://questionsmedicales.fr/author/Lifang%20Guo", "affiliation": { "@type": "Organization", "name": "Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China." } }, { "@type": "Person", "name": "Anders Larsson", "url": "https://questionsmedicales.fr/author/Anders%20Larsson", "affiliation": { "@type": "Organization", "name": "Section of Clinical Chemistry, Department of Medical Sciences, Uppsala University, Uppsala, Sweden." } }, { "@type": "Person", "name": "Megan Griffiths", "url": "https://questionsmedicales.fr/author/Megan%20Griffiths", "affiliation": { "@type": "Organization", "name": "Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA." } }, { "@type": "Person", "name": "Jun Yang", "url": "https://questionsmedicales.fr/author/Jun%20Yang", "affiliation": { "@type": "Organization", "name": "Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.", "datePublished": "2022-10-11", "url": "https://questionsmedicales.fr/article/36268143", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/6833078" } }, { "@type": "ScholarlyArticle", "name": "Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.", "datePublished": "2022-08-23", "url": "https://questionsmedicales.fr/article/35997934", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12013-022-01089-x" } }, { "@type": "ScholarlyArticle", "name": "A rapid fluorescent aptasensor for point-of-care detection of C-reactive protein.", "datePublished": "2022-06-04", "url": "https://questionsmedicales.fr/article/35714415", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.talanta.2022.123661" } }, { "@type": "ScholarlyArticle", "name": "C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.", "datePublished": "2022-07-09", "url": "https://questionsmedicales.fr/article/35821191", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejim.2022.07.001" } }, { "@type": "ScholarlyArticle", "name": "C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35766701", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/1806-9282.20220236" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Protéines angiogéniques", "item": "https://questionsmedicales.fr/mesh/D042501" }, { "@type": "ListItem", "position": 5, "name": "Protéines angiostatiques", "item": "https://questionsmedicales.fr/mesh/D043165" }, { "@type": "ListItem", "position": 6, "name": "Endostatines", "item": "https://questionsmedicales.fr/mesh/D043169" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Endostatines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Endostatines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Endostatines", "description": "Comment diagnostiquer une anomalie d'endostatine ?\nQuels examens sont utilisés pour évaluer l'angiogenèse ?\nLes biopsies sont-elles utiles pour les endostatines ?\nY a-t-il des marqueurs tumoraux associés aux endostatines ?\nComment les niveaux d'endostatine varient-ils ?", "url": "https://questionsmedicales.fr/mesh/D043169?mesh_terms=C-Reactive+Protein&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Endostatines", "description": "Quels symptômes sont liés à une faible endostatine ?\nLes symptômes d'angiogenèse excessive sont-ils visibles ?\nComment l'angiogenèse affecte-t-elle la santé ?\nLes symptômes varient-ils selon le type de cancer ?\nY a-t-il des symptômes spécifiques aux traitements d'endostatines ?", "url": "https://questionsmedicales.fr/mesh/D043169?mesh_terms=C-Reactive+Protein&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Endostatines", "description": "Peut-on prévenir le cancer avec des endostatines ?\nQuels modes de vie favorisent une bonne régulation des endostatines ?\nY a-t-il des études sur la prévention par endostatines ?\nLes antioxydants influencent-ils les niveaux d'endostatines ?\nLes endostatines peuvent-elles être utilisées en prévention primaire ?", "url": "https://questionsmedicales.fr/mesh/D043169?mesh_terms=C-Reactive+Protein&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Endostatines", "description": "Comment les endostatines sont-elles utilisées en oncologie ?\nQuels médicaments ciblent les endostatines ?\nLes endostatines sont-elles administrées par voie orale ?\nQuels sont les effets des traitements par endostatines ?\nY a-t-il des combinaisons de traitements avec endostatines ?", "url": "https://questionsmedicales.fr/mesh/D043169?mesh_terms=C-Reactive+Protein&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Endostatines", "description": "Quelles complications peuvent survenir avec les traitements d'endostatines ?\nLes endostatines peuvent-elles causer des effets secondaires graves ?\nComment gérer les complications liées aux endostatines ?\nLes complications varient-elles selon le type de cancer traité ?\nY a-t-il des risques à long terme associés aux endostatines ?", "url": "https://questionsmedicales.fr/mesh/D043169?mesh_terms=C-Reactive+Protein&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Endostatines", "description": "Quels facteurs augmentent le risque de cancer lié aux endostatines ?\nL'hérédité influence-t-elle les niveaux d'endostatines ?\nLe mode de vie affecte-t-il les niveaux d'endostatines ?\nLes infections chroniques sont-elles un facteur de risque ?\nLe stress a-t-il un impact sur les niveaux d'endostatines ?", "url": "https://questionsmedicales.fr/mesh/D043169?mesh_terms=C-Reactive+Protein&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie d'endostatine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins peuvent mesurer les niveaux d'endostatine pour évaluer l'angiogenèse." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer l'angiogenèse ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie par résonance magnétique (IRM) et l'échographie peuvent être utilisés." } }, { "@type": "Question", "name": "Les biopsies sont-elles utiles pour les endostatines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les biopsies tumorales peuvent aider à évaluer l'expression d'endostatines." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs tumoraux associés aux endostatines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études montrent des corrélations avec des marqueurs comme le VEGF." } }, { "@type": "Question", "name": "Comment les niveaux d'endostatine varient-ils ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux peuvent varier selon le type de cancer et le stade de la maladie." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une faible endostatine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une faible endostatine peut être associée à une progression tumorale et à des douleurs." } }, { "@type": "Question", "name": "Les symptômes d'angiogenèse excessive sont-ils visibles ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des saignements ou des douleurs peuvent survenir." } }, { "@type": "Question", "name": "Comment l'angiogenèse affecte-t-elle la santé ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Une angiogenèse excessive peut conduire à des tumeurs et à des complications vasculaires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de cancer ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la localisation et du type de cancer." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques aux traitements d'endostatines ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires comme des nausées ou des réactions cutanées peuvent survenir." } }, { "@type": "Question", "name": "Peut-on prévenir le cancer avec des endostatines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches suggèrent que les endostatines pourraient réduire le risque de cancer en inhibant l'angiogenèse." } }, { "@type": "Question", "name": "Quels modes de vie favorisent une bonne régulation des endostatines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et l'exercice régulier peuvent aider à maintenir des niveaux sains." } }, { "@type": "Question", "name": "Y a-t-il des études sur la prévention par endostatines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs études cliniques examinent leur rôle préventif dans le cancer." } }, { "@type": "Question", "name": "Les antioxydants influencent-ils les niveaux d'endostatines ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines recherches indiquent que les antioxydants peuvent moduler l'angiogenèse." } }, { "@type": "Question", "name": "Les endostatines peuvent-elles être utilisées en prévention primaire ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont principalement étudiées pour le traitement, mais des recherches en prévention sont en cours." } }, { "@type": "Question", "name": "Comment les endostatines sont-elles utilisées en oncologie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont explorées comme traitements pour inhiber la croissance tumorale en bloquant l'angiogenèse." } }, { "@type": "Question", "name": "Quels médicaments ciblent les endostatines ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées comme les inhibiteurs de VEGF sont souvent utilisés." } }, { "@type": "Question", "name": "Les endostatines sont-elles administrées par voie orale ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles sont généralement administrées par injection en raison de leur nature protéique." } }, { "@type": "Question", "name": "Quels sont les effets des traitements par endostatines ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent réduire la taille des tumeurs et améliorer la survie des patients." } }, { "@type": "Question", "name": "Y a-t-il des combinaisons de traitements avec endostatines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être combinées avec des chimiothérapies pour une efficacité accrue." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les traitements d'endostatines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des infections ou des réactions allergiques peuvent se produire." } }, { "@type": "Question", "name": "Les endostatines peuvent-elles causer des effets secondaires graves ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme l'hypertension ou des problèmes hémorragiques peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer les complications liées aux endostatines ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance médicale régulière et un ajustement des doses peuvent aider à gérer les complications." } }, { "@type": "Question", "name": "Les complications varient-elles selon le type de cancer traité ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent varier en fonction du type de cancer et du traitement associé." } }, { "@type": "Question", "name": "Y a-t-il des risques à long terme associés aux endostatines ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études sont nécessaires pour évaluer les effets à long terme des traitements par endostatines." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de cancer lié aux endostatines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge, le tabagisme et l'obésité peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'hérédité influence-t-elle les niveaux d'endostatines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer peuvent influencer les niveaux d'endostatines." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il les niveaux d'endostatines ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent affecter les niveaux." } }, { "@type": "Question", "name": "Les infections chroniques sont-elles un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections chroniques peuvent augmenter le risque de cancer et influencer l'angiogenèse." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les niveaux d'endostatines ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que le stress chronique peut influencer les niveaux d'endostatines et l'angiogenèse." } } ] } ] }

Sources (10000 au total)

C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.

The prognostic role of CRP (C-reactive protein) in gynecological tumors has been previously reported in individual studies, but whether CRP can be used as a separate potential prognostic factor has no... A systematic search was carried out to find the literature evaluating the predictive role of CRP in the prognosis of gynecological cancer patients. For the purpose of determining the relationship betw... A total of 19 studies, including 4062 patients, were analyzed retrospectively. The FIGO stage was related to the CRP level (OR = 0.43, 95% CI: 0.19-1.00). Age, lymph node metastasis, and histological ... CRP may be utilized as a prognostic indicator for a variety of gynecologic malignancies, including cervical cancer, ovarian cancer, endometrial cancer, and vulvar cancer....

C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.

To evaluate the association between C-reactive protein (CRP) and 10-year risk of cardiovascular (CV) events using the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA), b... ERS-RA was calculated in 1,251 "Cardiovascular Obesity and Rheumatic Disease Study (CORDIS)" database patients [(age 60.4(9.3) years; 78% female; disease duration, 11.6(8) years; CDAI, 9(9); CRP, 6.8(... The mean (SD) 10-year risk of CV events was 12.9% (10). After adjusting for the use of DMARDs and biologics, CRP concentrations were significantly associated with 10-year risk of CV events (coefficien... In a large cohort of RA patients without previous cardiovascular events, a 20 mg/L increase in CRP concentrations was associated with a 1% increase in 10-year risk of CV events. This suggests that act...

C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.

Chronic hepatitis C (CHC) is one of the most important health problems affecting the significant rate of world population and it may lead to cirrhosis and hepatocellular carcinoma. C-reactive protein ... Patients with CHC infection who visited outpatient and inpatient internal medicine clinics of our institution between January 2021 and December 2021 were enrolled to this retrospective study. CLR of t... Median CLR of CHC and control subjects was 2.61 (5.13%) and 0.31 (0.37%), respectively. CLR of the CHC group was significantly increased compared to the CLR of the controls (p<0.001). There was a sign... Increased CLR in patients with CHC may be an alarming finding of liver fibrosis, as CLR is associated with both CHC and hepatic fibrosis....

Serum C-reactive protein levels are associated with clinical pregnancy rate after

To assess whether low-grade inflammation, measured by serum high-sensitivity C-reactive protein (hsCRP) levels, is associated with... A retrospective study.... University-affiliated IVF center.... In the present study, 875 women of normal weight who underwent their first fresh embryo transfer (ET) cycles for IVF treatment were divided into three groups according to serum concentrations of hsCRP... Serum from women undergoing IVF was collected on days 2-4 of a spontaneous menstrual cycle prior to the commencement of ovarian stimulation.... The IVF outcomes included implantation, biochemical pregnancy, clinical pregnancy, miscarriage and live birth rates.... The women were divided into three groups according to the baseline serum levels of hsCRP as follows: low hsCRP (<1 mg/L; n=517), medium hsCRP (1-3 mg/L; n= 270), high hsCRP (>3 mg/L; n=88). The matern... Among women of normal weight undergoing their first IVF treatment, it was found that low-grade inflammation was associated with reduced clinical pregnancy and live birth rates following fresh ET cycle...

Mortality Risk in Pediatric Sepsis Based on C-reactive Protein and Ferritin Levels.

Interest in using bedside C-reactive protein (CRP) and ferritin levels to identify patients with hyperinflammatory sepsis who might benefit from anti-inflammatory therapies has piqued with the COVID-1... A prospective, observational cohort study.... Children with sepsis and organ failure in nine pediatric intensive care units in the United States.... Two hundred and fifty-five children were enrolled. Five distinct clinical multi-trajectory groups were identified. Plasma CRP (mg/dL), ferritin (ng/mL), and 31 cytokine levels were measured at two tim... Group 1 had normal CRP and ferritin levels ( n = 8; 0% mortality); Group 2 had high CRP levels that became normal, with normal ferritin levels throughout ( n = 80; 5% mortality); Group 3 had high ferr... Bedside CRP and ferritin levels can be used together to distinguish groups of children with sepsis who have different systemic inflammation cytokine responses and mortality risks. These data suggest f...